By Joshua Kirby

Shares in telehealth company Hims & Hers skyrocketed in premarket trading following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform, a move that would end a legal spat between the two companies.

Hims & Hers, which markets consumer drugs ranging from treatments for weight loss and erectile dysfunction in men, to treatments for menopausal symptoms in women, is set to offer Novo Nordisk's blockbuster Wegovy on its platform, Bloomberg reported, citing an unnamed source.

Shares in Hims & Hers more than doubled in premarket trading to $23.92, according to Nasdaq data. Nordisk shares gained less dramatically in European morning trading, rising 1.4% to 251.45 Danish krone.

A tie-up would bring an end to a dispute between the company and Denmark-based Novo Nordisk, which last month filed a lawsuit against Hims & Hers that accused the company of violating patents covering Wegovy and fellow weight-loss treatment Ozempic. The company hit back at the lawsuit, which it described as an attack on a more affordable option.

Hims & Hers shares fell sharply following news of the lawsuit was revealed as investors feared a hit to sales.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

(END) Dow Jones Newswires

March 09, 2026 05:58 ET (09:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.